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Background: Recent data suggest that concentrations of lipoprotein(a) [Lp(a)] may be inversely associated with the
risk of diabetes. This study analyzed the relationships between Lp(a) and both diabetes and insulin resistance in an
adult cohort from the island of Gran Canaria, Spain.
Methods: Lp(a), homeostasis model assessment for insulin resistance (HOMA-IR) and conventional risk factors for
diabetes were assessed in a sample of 1,030 adult individuals participating in a cross-sectional population-based
epidemiological survey in the city of Telde. Diabetes was defined according to the WHO 1999 criteria, or as a
previous diagnosis of diabetes. To identify patients at risk for diabetes, an Lp(a) cutoff level of 46 mg/dl was
selected previously using classification and regression tree analysis. A multivariate logistic regression model with L2-
regularization was used to assess the independent effect of Lp(a) on diabetes and its interactions with variables
traditionally linked to the disease. Additionally, to investigate the effect of Lp(a) on insulin resistance, a parametric
model was developed to describe the relationship between age and HOMA-IR values in subjects with levels of Lp
(a) ≤46 or >46 mg/dl.
Results: Along with variables known to be associated with diabetes, including age, mean blood pressure, serum
triglycerides, and an interaction term between age and low HDL cholesterol, the logistic model identified a
significant inverse association for diabetes and the interaction term between age and Lp(a) levels >46 mg/dl.
According to the proposed parametric model, HOMA-IR was significantly lower in subjects of all ages who had Lp
(a) levels >46 mg/dl.
Conclusions: These results suggest that the age-related increase in the probability of having diabetes is
significantly lower in subjects with Lp(a) levels >46 mg/dl. This could be explained in part by a lower insulin
resistance in this subset of the population.
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Lipoprotein(a) [Lp(a)] is a plasma lipoprotein consisting
of a LDL-like particle with a molecule of apolipoprotein
B100 covalently linked to a very large additional glyco-
protein known as apolipoprotein(a). Elevated Lp(a) levels
constitute an independent risk factor for cardiovascular
disease in the general population [1].
Lp(a) concentrations show considerable variation in
healthy individuals, and are controlled mainly by genet-
ics [2,3]. Nearly 90% of Lp(a) variation depends on bio-
synthesis of the distinctive apolipoprotein(a) protein,
which is encoded by the LPA locus [2]. Many classic and
novel risk factors have been investigated to determine
whether they explain the higher risk of cardiovascular
disease among people with diabetes [4-6]. In particular,
several studies have examined the possibility that type 2
diabetes could influence Lp(a) concentrations. The
results of several small case–control studies have been
controversial. Subjects with diabetes have been found to
have higher [7,8], similar [9] or lower levels of Lp(a) [10]
than controls without diabetes. Using a different ap-
proach to analyze the interaction between Lp(a) and dia-
betes, a more recent prospective study [11] of healthy
US women aged 45 years or older (Women’s Health
Study [WHS]) revealed an inverse association between
Lp(a) and the risk of incident type 2 diabetes. The
authors replicated their findings in a Danish population-
based cohort (Copenhagen City Heart Study [CCHS])
with prevalent diabetes. These findings suggest that Lp
(a) has opposite effects on the risks of cardiovascular
disease and diabetes, increasing the former and decreas-
ing the latter.
The aim of the present study was to examine the rela-
tionships between Lp(a) concentrations and both dia-
betes and insulin resistance in a cohort of adult subjects
from the general population of the Canary Islands,
Spain.
Research design and methods
Subjects and measurements
The study population was composed of 1,030 adult sub-
jects (≥30 years-old) who were participating in a cross-
sectional population-based study in Telde, a city located
on the island of Gran Canaria, Canary Islands, Spain.
The design of this survey was described previously [12].
Participants were selected randomly from the local cen-
sus. All subjects provided written informed consent for
participation in the study, which was approved by the
ethics committee of the Hospital Universitario Insular of
Las Palmas.
Subjects filled out a survey questionnaire, underwent
physical examination, gave fasting blood samples, and,
except for those with known diabetes, underwent a 75-g
standardized oral glucose tolerance test (OGTT).Diabetes was defined as a previous diagnosis of dia-
betes with ongoing treatment with oral agents and/or
insulin or was defined using the 1999 WHO diagnostic
criteria (fasting plasma glucose ≥7.0 mmol/l and/or 2-
h plasma glucose ≥11.1 mmol/l) [13]. A total of 128
subjects were classified as having type 2 diabetes, while
902 did not have diabetes. The homeostasis model as-
sessment for insulin resistance (HOMA-IR) was calcu-
lated according to the formula HOMA-IR = fasting
insulin (mU/l) × fasting plasma glucose (mmol/l)/22.5
[14]. Plasma insulin was measured by a chemilumines-
cent assay (Elecsys 2010; Roche Diagnostics, Basel,
Switzerland) and Lp(a) was measured by nephelometry,
using a Dimension RxL autoanalyzer (Dade-Behring,
Liederbach, Germany).
Statistical analysis
A classification and regression tree (CART) analysis
selected an Lp(a) cutoff level of 46 mg/dl for the identifi-
cation of patients at risk for diabetes. CART is a non-
parametric validated statistical procedure in which
classification and regression trees are constructed to pre-
dict an outcome variable from among a large number of
variables and their interactions. Explanatory variables
can be categorical and/or numeric [15]. To analyze the
eventual effect of Lp(a) on diabetes, a multivariate logis-
tic analysis was carried out. Variables entered into the
model were Lp(a) (with categories >46 and ≤46 mg/dl),
age, sex, presence of abdominal obesity (defined as a
waist circumference ≥102 cm for men and ≥88 cm for
women) [16], blood pressure (entered as mean arterial
pressure [MAP]), low levels of HDL cholesterol (HDL
cholesterol <40 mg/dl for men and <50 mg/dl for
women) [16], serum triglycerides (logarithmic scale),
LDL cholesterol, and self-reported use of statins. Levels
of triglycerides were logarithmically transformed to re-
duce skewness. All variables in the groups with or with-
out diabetes were checked for outliers. In order to
explore all possible interactions, we used a variant of lo-
gistic regression with L2-regularization to fit models with
interactions [17]. A forward selection procedure of vari-
ables and their interactions was performed based on the
Akaike’s information criterion. The model was fitted
using the iteratively reweighted ridge regressions algo-
rithm. Odd-ratios of interest were computed from the
obtained model along with estimated 95% confidence
intervals.
To further explore glucose homeostasis based on
levels of Lp(a), the relationship between age and
HOMA-IR values (in log scale) was modeled as follows:
E log HOMA IRð Þ½ jLp að Þ ¼ θ þ β ageþ γ
 Lp að Þ46  age2:
Table 1 Characteristics of the population according to the presence or absence of diabetes
Total (N= 1030) Diabetes (N= 128) No diabetes (N= 902) p-value
Age (years) 48.0 ± 11.9 58.9 ± 10.4 46.5 ± 11.3 <0.001
Male / Female (%) 43.5 / 56.5 57.8 / 42.2 41.5 / 58.5 <0.001
BMI (kg/m2) 28.2 ± 5.0 31.0 ± 5.4 27.8 ± 4.8 <0.001
Waist (cm) 97 ± 14 107 ± 12 95 ± 13 <0.001
Abdominal obesity (%) 57.4 83.6 53.7 <0.001
Systolic blood pressure (mmHg) 119 ± 16 134 ± 16 117 ± 15 <0.001
Diastolic blood pressure (mmHg) 73 ± 10 79 ± 10 72 ± 10 <0.001
Smoking (%) 24.2 11.7 25.9 <0.001
Current use of statins (%) 14.8 29.7 12.6 <0.001
Total cholesterol (mg/dl) 212 ± 38 217 ± 44 212 ± 37 0.170
LDL cholesterol (mg/dl) 131 (112–154) 134 (106–157) 131 (112–154) 0.833
Triglycerides (mg/dl) 103 (74–148) 132 (102–190) 100 (71–142) <0.001
HDL cholesterol (mg/dl) 54 ± 12 50 ± 13 55 ± 12 <0.001
Low HDL-cholesterol (%) 21.4 35.2 19.4 <0.001
Lp(a) (mg/dl) 13.8 (5.8–32) 13.1 (4.8–29.3) 13.8 (6.0–33.1) 0.354
Lp(a) >46 mg/dl (%) 13.7 9.4 14.3 0.129
Fasting plasma glucose (mg/dl) 91 (82–101) 138 (116–177) 88 (82–97) <0.001
HbA1c (%) 5.4 (5.1–5.7) 6.8 (6.0–8.2) 5.3 (5.1–5.6) <0.001
HOMA-IR 1.6 (1.0–2.7) 4.0 (2.7–6.6) 1.5 (1.0–2.3) <0.001
Serum creatinine (mg/dl) 0.8 (0.7–0.9) 0.8 (0.7–1.0) 0.8 (0.7–0.9) 0.001
Results are expressed as mean ± SD or median (interquartile range) for variables with skewed distribution.
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Lp(a) is greater than 46 mg/dl and a value of 0 if Lp(a) is
equal to or less than 46 mg/dl. All statistical analyses
were performed using the R-package stepPlr.Table 2 Results of multivariate logistic regression
analysis
Factor Cohort OR (95% CI)
Age (per year) Lp(a) ≤46 mg/dl/Normal
HDL-C
1.075 (1.055 ; 1.095)
Lp(a) >46 mg/dl/Normal
HDL-C
1.062 (1.039 ; 1.085)
Lp(a) ≤46 mg/dl/Low
HDL-C
1.087 (1.066 ; 1.109)
Lp(a) >46 mg/dl/Low
HDL-C
1.074 (1.050 ; 1.098)
Mean arterial pressure All subjects 1.060 (1.039 ; 1.081)
Log-Triglycerides All subjects 2.317 (1.417 ; 3.787)
HDL-C: HDL cholesterol.Results
Table 1 shows the demographic characteristics of the
survey population. The median level of Lp(a) was 14.0
(interquartile range: 5.1–29.8) mg/dl in subjects with
diabetes and 13.8 (6.0–33.0) mg/dl in subjects without
diabetes (p= 0.35). There was no significant difference in
the percentage of individuals with Lp(a) >46 mg/dl be-
tween the groups with or without diabetes (9.4% vs.
14.3%; p= 0.13). A significantly higher percentage of sub-
jects with diabetes reported taking statins compared to
subjects without diabetes (29.7% vs. 14.8%; p< 0.001).
Subjects with Lp(a) >46 mg/dl were older than those
with Lp(a) ≤46 mg/dl (50.0 ± 11.9 years vs. 47.7 ±
11.9 years, p= 0.034). The gender distribution, the per-
centage of postmenopausal women, and the percentage
of women on hormone replacement therapy was not sig-
nificantly different between groups with levels of Lp(a)
≤46 vs. >46 mg/dl.
As expected, most of the variables traditionally linked
to diabetes were independently associated with the out-
come in the multivariate logistic regression model: age(p< 0.001), MAP (p< 0.001), serum triglycerides
(p= 0.001), and the interaction term between age and
low HDL cholesterol (p= 0.007). In addition, there was a
significant inverse association between diabetes and the
interaction term age × Lp(a) >46 mg/dl (p= 0.048). As
both HDL cholesterol and Lp(a) >46 mg/dl showed sig-
nificant interactions with age, the association between
age and diabetes was different in each of the four
cohorts determined by the two factors (Table 2). Figure 1
shows the probability of diabetes according to age and
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Lp(a) > 46 mg/dL
Figure 1 Adjusted probability of diabetes mellitus according to age and status of Lp(a) status.
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cholesterol.
Figure 2 shows the adjustment of log (HOMA-IR)
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Lp(a) < 46 mg/dl
Figure 2 Parametric adjustment of HOMA-IR (log scale) for subjects w
≤46 mg/dl.with levels of Lp(a) >46 and for subjects with levels of
Lp(a) ≤46 mg/dl. Predicted values of log (HOMA-IR)
were higher in subjects with Lp(a) levels ≤46 mg/dl. The
differences increased with the age, although the lower60 70 80 90
e (years)
ith Lp(a) levels >46 mg/dl and subjects with Lp(a) levels
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difference between predicted values of log (HOMA-IR)
was greater than 0 across all ages.
Discussion
The major finding in this population-based study was
that after adjusting for established risk factors for dia-
betes (age, abdominal obesity, blood pressure, and serum
levels of HDL cholesterol and triglycerides), the age-
related increase in the probability of having diabetes was
significantly lower in subjects with higher levels of Lp(a).
This was a cross-sectional study, so no causal associa-
tions can be inferred from the results. In theory, either
diabetes by itself or any accompanying condition could
contribute to increase Lp(a) levels over the lifespan of
each individual. However, it is well established that Lp(a)
concentrations are not significantly affected by environ-
mental factors. Instead, most of the variance in plasma
Lp(a) is determined genetically. Alternatively, because
both Lp(a) and diabetes increase the risk of cardiovascu-
lar disease, mortality rates may be increased at earlier
ages in subjects with both risk factors. This would result
in a greater proportion of individuals with low levels of
Lp(a) among older survivors with diabetes. However, this
possibility is inconsistent with recent data showing that,
in contrast to what is observed in the general popula-
tion, plasma Lp(a) levels are not significantly associated
with cardiovascular risk in patients with diabetes [18].
Therefore, a more plausible explanation for our findings
is that the age-related rate of progression to diabetes is
slower in subjects with high levels of Lp(a). This inter-
pretation is in accordance with the results of the WHS,
a large prospective study involving more than 26,000
healthy middle-aged US women, which found that the
cumulative probability of incident type 2 diabetes was
inversely correlated with basal Lp(a) levels [11]. How-
ever, in contrast with the WHS and the CCHS, our study
found a threshold effect for Lp(a). Specifically, the age-
related risk of diabetes was lower for subjects with Lp(a)
levels above 46 mg/dl.
We also observed that values of HOMA-IR, a surro-
gate marker of insulin resistance were lower in subjects
with Lp(a) levels >46 mg/dl, suggesting that extremely
high levels of Lp(a) are associated with less resistance to
insulin. Some previous population-based studies failed
to demonstrate any relationship between insulin sensitiv-
ity and Lp(a) levels [19]. However, in their seminal inves-
tigations in the 1970s, Dahlën & Berg [20] found that,
compared to controls with Lp(a) levels that were un-
detectable by agarose electrophoresis, older men with
detectable Lp(a) levels showed higher levels of post-load
blood glucose and lower levels of both fasting and post-
load insulin. More recently, using the euglycemic clamp
technique, Haffner et al [21] observed a positivecorrelation between insulin sensitivity and Lp(a) levels in
normoglycemic men. In a large sample of subjects in the
San Antonio Family Heart Study, the same authors
demonstrated that Lp(a) levels are inversely correlated
with fasting insulin levels and with insulin and glucose
concentrations measured 2 hours after an OGTT [22].
Finally, several studies have shown a positive correlation
between Lp(a) and HDL cholesterol and a negative cor-
relation between Lp(a) and triglycerides [23], indicating
that Lp(a) shows an inverse relationship with the athero-
genic dyslipidemia characteristically associated with in-
sulin resistance. There is no obvious explanation for this
inverse correlation between Lp(a) and both diabetes and
insulin resistance. Because Lp(a) levels are determined
mainly by genetic mechanisms, one possibility is that
genetic polymorphisms associated with increased levels
of Lp(a) are in linkage disequilibrium with gene(s) that
protect against insulin resistance.
Conclusions
The present report suggests that the probability of hav-
ing diabetes increases with age but that this increase is
lower in subjects with serum levels of Lp(a) higher than
46 mg/dl. Further studies are needed to clarify the na-
ture of the interaction between Lp(a) and the risk of
diabetes.
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